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Polyethylenimine (PEI) is considered to be a promising non-viral gene delivery vector. To solve the toxicity versus
efficacy and tumor-targeting challenges of PEI used as gene delivery vector, we constructed a novel non-viral vector
DR5-TAT-modified Pluronic-PEI (Pluronic-PEI-DR5-TAT), which was based on the attachment of low-molecular-weight
polyethylenimine (LMW-PEI) to the amphiphilic polymer Pluronic to prepare Pluronic-modified LMW-PEI (Pluronic-PEI).
This was then conjugated to a multifunctional peptide containing a cell-penetrating peptide (TAT) and a synthetic
peptide that would bind to DR5—a receptor that is overexpressed in cancer cells. The vector showed controlled
degradation, favorable DNA condensation and protection performance. The Pluronic-PEI-DR5-TAT/DNA complexes at
an N/P ratio of 15:1 were spherical nanoparticles of 122 ± 11.6 nm and a zeta potential of about 22 ± 2.8 mV. In vitro
biological characterization results indicated that Pluronic-PEI-DR5-TAT/DNA complexes had a higher specificity for the
DR5 receptor and were taken up more efficiently by tumor cells than normal cells, compared to complexes formed
with PEI 25 kDa or Pluronic-PEI. Thus, the novel complexes showed much lower cytotoxicity to normal cells and higher
gene transfection efficiency in tumor cells than that exhibited by PEI 25 kDa and Pluronic-PEI. In summary, our novel,
degradable non-viral tumor-targeting vector is a promising candidate for use in gene therapy.
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In recent years, gene therapy has been considered to be
the most promising strategy for the treatment of unre-
sectable cancer. The vital technology for the success of
gene therapy is gene delivery, which is greatly limited by
the lack of a safe and efficient delivery system [1, 2].
Therefore, there is a critical need to develop a novel
gene delivery system that can fulfill the special require-
ments for successful gene delivery, such as high transfec-
tion efficiency and low cytotoxicity as well as high level
of targeting specificity to cancer cells. Over the past
few decades, non-viral gene vectors, including cationic* Correspondence: zhengyongxia@163.com; lena_310@163.com
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license, and indicate if changes were made.polymer, have attracted much attention due to their
non-immunogenicity, structural diversity, and ease of
production as compared to viral vectors [3–7]. Polyethyle-
nimine (PEI) is a promising candidate among polycationic
polymers used for transfection, which provides superior
transfection efficiency due to its effective DNA condensa-
tion, uptake via the endocytosis pathway, and endosomal
escape capacity [8–10]. However, there are still three out-
standing issues to be solved if PEI is to be used as a gene
carrier [11–14]. First and foremost, high-molecular-weight
(HMW; ≥25 kDa) PEI has high transfection efficiency but
also shows high cytotoxicity compared to low-molecular-
weight (LMW; ≤2000 Da) PEI which displays lower cyto-
toxicity but limited delivering efficiency. Besides, PEI
delivery relies simply on the electrostatic attraction be-
tween the positively charged polymer and negatively
charged cells, which is non-selective. Last but not least,istributed under the terms of the Creative Commons Attribution 4.0 International
y/4.0/), which permits unrestricted use, distribution, and reproduction in any
to the original author(s) and the source, provide a link to the Creative Commons
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philicity increases, but this also reduces the ability to
penetrate cellular membranes.
To overcome these limitations, considerable attempts
have been made to modify PEI. Degradable PEIs have
been formed by cross-linking with PEG/Pluronic chains
that contain biodegradable moieties, and targeted vec-
tors have been developed by combining PEI with ligands
for cell- or tissue-specific targeting [15–20].
In our previous study, we developed a series of PEI-
modified block polyplexes by grafting PEI with nonionic
amphiphilic surfactant polyethers-Pluronic (Pluronic-PEI),
which have been confirmed to enhance DNA condensa-
tion, cellular uptake, and transgene expression [21]. More-
over, the hydrophobic propylene oxide chain was thought
to improve the biocompatibility of the vector, improve its
stability, and prolong its circulation in blood in the same
manner as PEGylation [13, 15, 16]. But the DNA/Pluro-
nic-PEI complex could also be internalized into normal
cells. To improve the targeting of the gene carrier for effi-
cient cancer therapy, specific ligands which can bind to
target cell-surface receptors, such as peptides, folate and
antibodies, have been coupled to gene delivery vectors,
which can trigger receptor-mediated endocytosis [22–24].
Receptor 1 (DR4) and receptor 2 (DR5) of tumor ne-
crosis factor-α-related apoptosis-inducing ligand (TRAIL)
are highly expressed on most tumor cells and thus
present an ideal target for active targeting therapy
[25–27]. A synthetic peptide, with the amino acid se-
quence YCKVILTHRCY, has been shown to bind specific-
ally with DR5 [28, 29]. Furthermore, cell-penetrating
peptides (CPPs) have been widely used in gene delivery
systems to allow macromolecules to penetrate the cell
membrane and target the cell nucleus. In addition, CPPs
can enhance the transfection efficiency of PEI with low
molecular weight [30–32]. The transduction domain of
CPPs has been demonstrated to be an amino acid se-
quence of RKKRRQRRR (TAT) [33]. To take advantage of
both of these peptides, we combined DR5-targeting pep-
tide and linked it with TAT to obtain as a new multifunc-
tional peptide (DR5-TAT) for use in our Pluronic-PEI
vector. The multifunctional peptide is expected to not
only target DR5 high expressed tumor cells but also pro-
mote the transmembrane ability and enhance transfection
efficiency of the gene delivery system.
The overall preparation strategy for our new vector
first involved preparation of DR5-TAT. Subsequently,
this was coupled to Pluronic-PEI using cross-linking to
prepare the final vector DR5-TAT-modified Pluronic-PEI
(Pluronic-PEI-DR5-TAT), and after synthesis, its chem-
ical and biophysical characterization was carried out. In
addition, we prepared a model delivery system using re-
porter gene DNA (Pluronic-PEI-DR5-TAT/DNA) and
evaluated its targeting effect, gene transfection efficiency,and safety in vitro. The results showed that the con-
structed novel gene delivery system has high non-viral
transfection efficiency, high tumor cells, and tissue-
specific targeting as well as good security and stability.
Methods
Synthesis of Pluronic-PEI and Pluronic-PEI-DR5-TAT
Pluronic-grafted PEI polyplexes (Pluronic-PEI) were syn-
thesized as previously reported [21]. Briefly, PEI 2 kDa
(0.20 g, 0.10 mmol) was dissolved in anhydrous dichlo-
romethane (10 mL), and activated Pluronic (0.01 mmol)
was separately dissolved in anhydrous ethanol (10 mL).
PEI 2 kDa solution and Pluronic solution were then
slowly added to anhydrous dichloromethane (10 mL)
under constant stirring. The reaction was allowed to
proceed at 25 °C overnight. After that, the reaction
product was dialyzed against distilled water using a dia-
lysis membrane (molecular weight cutoff (MWCO)
7 kDa; Spectrum Laboratories, Rancho Dominguez, CA,
USA) at 4 °C for 48 h to remove byproducts. Finally, the
purified product was lyophilized and stored at −20 °C for
further use. The resulting sticky material was confirmed
to be Pluronic-PEI by IR and 1H NMR spectroscopy.
To obtain DR5-TAT-modified Pluronic-PEI (Pluronic-
PEI-DR5-TAT), 0.167 g N-succinimidyl-4-(N-maleimido-
methyl)cyclo-hexane-1-carboxylate (SMCC) was dissolved
in dimethyl sulfoxide (50 mL; 3.33 mg/mL), and Pluronic-
PEI (0.452 g) were dissolved in phosphate-buffered saline
(PBS; 50 mL; 0.1 M 9 mg/mL) [18]. Then, SMCC solution
was added dropwise to Pluronic-PEI solution (SMCC:
Pluronic-PEI = 2:1, mol/mol) with gentle stirring, and the
mixture was further incubated for 40 min at 25 °C to ob-
tain the maleimide-activated Pluronic-PEI. After that, the
DR5-TAT PBS solution (10 mg/mL) was reacted with the
maleimide-activated Pluronic-PEI solution (DR5-TAT:
maleimide-activated Pluronic-PE = 2:1, mol/mol). The re-
action mixture was stirred in the dark at 4 °C for 24 h. Fi-
nally, the reaction mixture was dialyzed (MWCO 7 kDa,
Spectrum Laboratories) against distilled water for 24 h
and lyophilized. After lyophilization, Pluronic-PEI-DR5-
TAT, a solid white product, was obtained (Fig. 1). The
identity of the material was confirmed using IR and 1H
NMR spectroscopy.
The control vectors Pluronic-PEI-DR5 and Pluronic-
PEI-TAT were synthesized in the same way as men-
tioned above.
Characterizations of Pluronic-PEI and Pluronic-PEI-DR5-TAT
The 1H NMR spectra of Pluronic-PEI and Pluronic-PEI-
DR5-TAT were recorded on a Mercury Plus 300 MHz
spectrometer (Varian, USA) using approximately 10 mg
sample dissolved in 0.6 mL deuterium oxide (D2O) at
25 °C. The IR spectra of Pluronic-PEI and Pluronic-PEI-
DR5-TAT were measured using a Fourier transform IR
Fig. 1 Synthetic scheme showing the preparation of Pluronic-PEI-DR5-TAT
Wu et al. Nanoscale Research Letters  (2016) 11:122 Page 3 of 13(FT-IR) spectrometer (Varian, USA). KBr pellets of
Pluronic-PEI and Pluronic-PEI-DR5-TAT were used in
the IR instrument. The FT-IR spectra were acquired
after 16 scans at 4000–400 cm−1.
Degradation of Pluronic-PEI-DR5-TAT
The degradability of Pluronic-PEI-DR5-TAT was investi-
gated under simulated in vivo conditions. Briefly, seven
samples of Pluronic-PEI-DR5-TAT were prepared (0.5 g
in 10 mL Dulbecco’s Modified Eagle’s medium (DMEM))
in centrifuge tubes. Then, tubes were incubated at 37 °C
and shaken at 100 rpm. At specified periods (ranging
from 5 to 60 h), a sample was lyophilized and the
molecular weight of the lyophilized material was deter-
mined using gel permeation chromatography and multi-
angle laser light scattering (laser wavelength, 690 nm).
Preparation of Pluronic-PEI-DR5-TAT/DNA Complexes
Pluronic-PEI-DR5-TAT/DNA complexes were formed at
predetermined N/P (nitrogen in cationic polymer to
phosphate in nucleic acid) ratios. A mass per charge of
43 for PEI and a mass per phosphate of 325 Da for DNA
were used to calculate the N/P ratio. An appropriate
amount of DNA (10 μg) was added into various amounts
of Pluronic-PEI-DR5-TAT solution, corresponding to N/
P ratios ranging from 1:1 to 25:1, into a final volume of
300 μL. The solution was gently vortexed for 30 s and
further incubated at 25 °C for 30 min.
Gel Retardation Assay of Complexes
Electrophoresis was performed to investigate the DNA
condensation ability of various amounts of polymer.Pluronic-PEI-DR5-TAT/DNA complexes were prepared
at various N/P ratios from 1:1 to 8:1 in a final volume.
The samples were electrophoresed on 1.0 % (w/v) agar-
ose gels with ethidium bromide (0.5 mg/mL) and ran
with Tris buffer for about 30 min at 100 V. DNA bands
were visualized using a UV (254 nm) illuminator.Particle Size, Zeta Potential, and Morphology of Complexes
The mean particle size and zeta potential of the Pluronic-
PEI-DR5-TAT/DNA complexes were analyzed at 25 °C
using laser light scattering (Zetasizer ZS90; Malvern
Instruments, Malvern, UK). Prior to measurement,
Pluronic-PEI-DR5-TAT/DNA complexes with N/P ratios
ranging from 1:1 to 25:1 were prepared as described
above. The surface morphology of Pluronic-PEI/DNA and
Pluronic-PEI-DR5-TAT/DNA samples (at N/P ratio of
15:1) was also observed under a transmission electron
microscope (TEM; H600; Hitachi, Tokyo, Japan).DNase I Protection and Release Assay of Complexes
A DNase I protection assay was performed to evaluate the
ability of Pluronic-PEI-DR5-TAT to protect DNA in com-
plexes. Each solution of Pluronic-PEI-DR5-TAT/DNA
complexes (at N/P ratio of 15:1) was divided equally and
incubated at 37 °C for 1 h with DNase I at various concen-
trations of 0, 0.15, 0.75, 1.5, 2.25, 3.75, 4.5, 5.25, 6, 6.75,
and 7.5 U DNase I/μg DNA. All of the samples were
treated with 250 mM EDTA (10 μL) for 10 min to inacti-
vate DNase I. Subsequently, the samples were further
mixed with 10 μL heparin sodium (250 U/mL) and incu-
bated at 25 °C for 120 min to displace DNA. Finally,
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extent of DNase I degradation in each sample.
PBS buffer solution containing dithiothreitol (DTT;
10 μL) was added to Pluronic-PEI-DR5-TAT/DNA solu-
tion to give a final concentration of 10 mM DTT, and the
dispersions were incubated for 60 min. A control using
PBS alone was also prepared. The samples were then
assessed by agarose gel electrophoresis as described above.
In vitro Cytotoxicity Evaluation
The cytotoxicity of polymers was evaluated in HeLa,
HepG2, and NIH 3T3 cells (5 × 103cells/well), which
were cultured in 96-well plates for 18–24 h to achieve
80 % confluency before treatment. Various carrier mate-
rials (Pluronic-PEI-DR5-TAT, Pluronic-PEI, PEI 25 kDa,
and PEI 2 K) at concentrations ranging from 5 to 160 μg/
mL were added and incubated for another 24 h. Then,
MTT reagent (20 μL; 5 mg/mL) was added to each well
followed by DMSO (150 μL) 4 h later to dissolve the for-
mazan crystals. Subsequently, the absorbance was mea-
sured at 570 nm using a microplate reader to assess the
metabolic activity of the cells. The viability of untreated
cells was set at 100 % (Acontrol), and the absorbance of
wells with medium and without cells was set as zero. The
relative cell viability (%) compared to control cells was cal-
culated using the formula Atest/Acontrol × 100 %.
Cellular Uptake and Competition Assay
DyLight-633 was used as a molecular probe to label PEI
25 kDa, Pluronic-PEI, and Pluronic-PEI-DR5-TAT. HeLa,
HepG2, and NIH 3T3 cells (5 × 105cells/well) were cul-
tured in six-well plates for 8–12 h to reach about 80 %
confluency before treatment. Labeled carrier materials at
various concentrations (0, 0.20, 0.40, and 0.80 μM) were
added, and the cells were incubated for 60 min. The cells
were then washed three times with PBS to remove
surface-associated complexes and were then trypsinized
and resuspended in the medium. The efficiency of cell
uptake was analyzed using a FACScan flow cytometer
(Becton Dickinson, San Jose, CA, USA). Untreated cells
were used as negative controls.
A competition assay was carried out to investigate DR5-
mediated uptake of Pluronic-PEI-DR5-TAT/DNA com-
plexes. Briefly, HeLa, HepG2, and NIH 3T3 cells were
preincubated with 20 mM DR5 for 15 min; cells were then
treated with Pluronic-PEI/DNA-cy3 and Pluronic-PEI-
DR5-TAT/DNA-cy3 in a final concentration of 1 mM for
30 min at 37 °C. Cells treated with Pluronic-PEI/DNA-cy3
and Pluronic-PEI-DR5-TAT/DNA-cy3 without any inhib-
ition was used as the control. Finally, the cells were
washed three times with PBS and visualized under an
Olympus I71-22/FL/PH inverted fluorescent microscope
(Olympus Corporation, Tokyo, Japan). For quantitative
analysis, HeLa, HepG2, and NIH 3T3 cells were treated asdescribed above and permeabilized with cell lysis buffer
(100 mL) before luciferase activity was measured in terms
of relative light units (RLU) according to the manufac-
turer’s instructions (Promega). RLU was normalized
against protein concentration in the cell extracts, which
was determined using a Micro-BCA protein assay kit.
Transfection Efficiency Assay
A green fluorescent protein (pEGFP-N2) plasmid was
used as a reporter gene to examine the ability of Pluronic-
PEI-DR5-TAT to transfect HeLa and HepG2 cells. Cells
(1 × 105 cells/well) were seeded in 24-well plates and incu-
bated for 18–24 h prior to the transfection experiments.
Different polymer/DNA complexes (containing 3 μg
pGL3) with various N/P ratios ranging from 1:1 to 15:1
were added to the cells and incubated for 4 h at 37 °C
under 5 % CO2 atm. After that, the medium was replaced
with fresh, serum-containing complete media, and the
cells were incubated for a further 48 h. Finally, the cells
were washed three times with PBS and visualized under a
fluorescent microscope.
A pGL3 plasmid control was also employed to exam-
ine the gene delivery efficiency of polymer. The cells
were treated as described above, and plasmid DNA
(pEGFP-N2; 3 μg per well) was applied. After incubation
for 48 h, fluorescence quantitative analysis was carried
out as described in the competition assay section.
Results and Discussion
Synthesis and Characterization of Pluronic-PEI-DR5-TAT
The preparation of Pluronic-PEI-DR5-TAT began when
free hydroxyl groups on the Pluronic polyether chains
were activated using succinimidyl carbonate and then
linked to the amino groups of to give Pluronic-PEI [21].
Next, SMCC was used as a cross-linker between the
remaining amino groups of Pluronic-PEI and the sulfhy-
dryl group on the multifunctional peptide DR5-TAT to
obtain Pluronic-PEI-DR5-TAT, as shown in Fig. 1.
The 1H NMR spectrum (Fig. 2a(I)) showed –CH2CH2
O– proton peaks at 3.5 ppm (Fig. 2a(I-1)) and –CH2CH2
NH– protons peaks at δ2.4–3.6 ppm (Fig. 2a(I-2, 3, 4)),
which were the characteristic signal of Pluronic-PEI as
conformed in our prior report [24]. Fig. 2a(II) shows the
1H NMR spectrum of Pluronic-PEI-DR5-TAT, in which
the integral of the signal is at 0.9 ppm (Fig. 2a(II-5)), in-
creased and the signals at 2.4–2.6 ppm (Fig. 2a(II-678))
decreased. Furthermore, proton peaks moved upfield
compared to those in Fig. 2a(I) owing to the electronic
screening effect resulting from DR5-TAT attachment.
These results indicate that DR5-TAT was successfully
linked to Pluronic-PEI.
The identity of Pluronic-PEI-DR5-TAT was also con-
firmed by FT-IR. As shown in Fig. 2b, compared with
the IR spectra of Pluronic-PEI, a phenyl signal appeared
Fig. 2 a 1H NMR spectra of (I) Pluronic-PEI and (II) Pluronic-PEI-DR5-TAT. b IR spectra of (I) Pluronic-PEI and (II) Pluronic-PEI-DR5-TAT. c Degradation
of Pluronic-PEI-DR5-TAT after incubation with buffer at 37 °C. Molecular weight (MW) was measured by gel permeation chromatography with
multi-angle laser light scattering (n = 3)
Table 1 Fitting of degradation degree of Pluronic-PEI-DR5-TAT
to different kinetic models
Model Equation R Mse
Zero-order kinetic Q = 0.0125t + 0.1157 0.9743 0.01123
First-order kinetic ln(1 − Q) = −0.285t + 0.0213 0.9968 0.00056
Higuchi Q = 0.1058t1/2 − 0.0047 0.9959 0.00108
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the phenyl group of DR5-TAT. This further confirmed
the successful coupling of DR5-TAT to Pluronic-PEI.
Degradation of Polyplexes
The degradability of gene vectors is important with re-
spect to safety. Non-degradable PEI vectors such as PEI
25 kDa may accumulate in vivo and cause potential
cytotoxicity due to the lack of degradation or excretion
pathways. It is therefore expected that the amide bonds
in Pluronic-PEI-DR5-TAT are susceptible to hydrolysis
leading to the generation of poloxamer oligomers and
low molecular weight PEI under physiological conditions
and resulting in low cytotoxicity [21]. The in vitro deg-
radation study (Fig. 2c) indicated that Pluronic-PEI-
DR5-TAT could be degraded slowly under simulatedin vivo conditions, and complete degradation took about
60 h, indicating that Pluronic-PEI-DR5-TAT could en-
sure transfection efficiency while reducing the toxic ef-
fect on cells.
To analyze the degradation kinetics of Pluronic-PEI-
DR5-TAT, the degradation curve was fitted to three dif-
ferent kinetic models (Table 1). As shown in Table 1, the
degradation profile of Pluronic-PEI-DR5-TAT could be
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on the model, the half-life of Pluronic-PEI-DR5-TAT is
about 30.7 h.
Particle Size, Zeta Potential, and Morphology of Complexes
Complex formation relies on a self-assembly process
between negatively charged plasmid DNA and posi-
tively charged polymer [12]; therefore, the ability of a
cationic polymer to condense DNA is a prerequisite
for effective gene delivery. Particle size also affects
gene delivery as complexes with smaller sizes tend to
accumulate in tumors due to the enhanced perme-
ation and retention (EPR) effect and internalize into
cells more quickly [34]. A positive surface charge is
also required for the complex to be able to bind to
negatively charged cell surfaces and facilitate cellular
uptake.
The particle size and zeta potential of Pluronic-PEI-
DR5-TAT/DNA complexes were determined at various
N/P ratios using dynamic light scattering, and nanopar-
ticles morphology was observed using TEM. The results
are shown in Fig. 3a–d. As shown in Fig. 3a, b, the
morphology of Pluronic-PEI-DR5-TAT/DNA complexes
was roughly spherical, which is similar to the Pluronic-Fig. 3 Particle size, zeta potential, and morphology of Pluronic-PEI-DR5-TAT
ratio of 15. b Morphology of Pluronic-PEI-DR5-TAT/DNA at N/P ratio of 15.
at various N/P ratios (n = 3). d Average zeta potential (mV) of Pluronic-PEI-DPEI/DNA complexes. However, compared to Pluronic-
PEI/DNA complexes, there was an increase in particle
size of about 28 nm, presumably owing to the presence
of DR5-TAT. The particle size of the complexes decreased
significantly as N/P ratio increased, which indicated that
condensation capability of polymers is strengthened as
charge increases (Fig. 3c). When the N/P ratio was at 15,
the particle size and the zeta potential of Pluronic-PEI-
DR5-TAT/DNA complexes were about 122 ± 11.6 nm and
22 ± 2.8 mV (Fig. 3c, d), respectively, which is very con-
venient for cell uptake. Moreover, all of the polymer/DNA
complexes (except Pluronic-PEI-DR5-TAT at the N/P ra-
tio of 1) were positively charged (Fig. 3d). As N/P ratio in-
creased from 1 to 25, the positive charge of the complexes
also increased, which is consistent with the following re-
sults of gel retardation assay.
DNase I Protection and Release Assay of Complexes
Protecting DNA from nuclease-mediated degradation is
the primary responsibility of any gene delivery carrier [35].
The DNA condensation capability of Pluronic-PEI-DR5-
TAT was measured by gel retardation assay. As shown in
Fig. 4a, the migration of the DNA plasmid was increas-
ingly retarded as the amount of the Pluronic-PEI-DR5-/DNA complex. a Morphology of Pluronic-PEI/DNA complexes at N/P
c Average particle sizes (nm) of Pluronic-PEI-DR5-TAT/DNA complexes
R5-TAT/DNA complexes with various N/P ratios (n = 3)
Fig. 4 a Agarose gel electrophoresis showing retardation of pGL3 plasmid DNA by Pluronic-PEI-DR5-TAT at different N/P ratios, 0:1 (DNA only),
1:1, 2:1, 4:1, 6:1, and 8:1. b Pluronic-PEI-DR5-TAT protects plasmid DNA DNase I-mediated degradation at various concentrations was estimated by
agarose gel electrophoresis. Naked DNA was used as control. c Influence of dithiothreitol on Pluronic-PEI-DR5-TAT/DNA complexes at various N/P
ratios (4:1, 6:1, 8:1). The last three lanes were treated with 10 mM DTT
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an N/P ratio of 4:1, confirming that Pluronic-PEI-DR5-
TAT binds to DNA and neutralizes its charge.
As shown in Fig. 4b, after the complexes solution were
incubated with different concentration of DNase I, DNA
was still protected from digestion by DNase I (lanes 2–
8), even at a concentration of 5.25 U DNase I/μg DNA
(lane 8), while naked DNA was degraded by DNase I at
a concentration of 0.08 U DNase I/μg DNA (lane 1),
which is consistent with the literature [36].
Figure 4c shows the release property of DNA from
complexes in the intracellular environment. DTT was
used to simulate the intracellular environment in vivo,
mediating the ester bond of Pluronic-PEI-DR5-TAT fis-
sion and testing the DNA release property of Pluronic-Fig. 5 Cytotoxicity of polyplexes at various concentrations in a HeLa, b He
polyplexes for a time period of 24 h (mean ± SD, n = 6)PEI-DR5-TAT (lanes 1–3). The vector without DTT was
used as control group (lanes 4–6). DNA release from
Pluronic-PEI-DR5-TAT was observed in the presence of
5.0 mM DTT, which simulated the 0.1–10 mM glutathi-
one found in vivo (lanes 1–3), compared to the control
group which showed completely retard plasmid DNA
migration (lanes 4–6). In contrast, there was almost no
DNA released from PEI 25 kDa/DNA complexes when
treated with DTT [37]. This result indicates that
Pluronic-PEI-DR5-TAT could dissociate easily in the
intracellular environment, which was similar to the re-
sults observed in our previous work, which showed that
Pluronic-PEI dissociation was most likely because DTT
mediated ester bond fission, leading to more DNA to re-
lease and enhancing gene expression.pG2, and c NIH 3T3 cells. The cells were incubated using different
Fig. 7 Competition inhibition assay of polyplexes. a The cellular uptake of Pluronic-PEI/DNA-cy-3 complexes in HeLa, HepG2, and NIH 3T3 cells
pretreated with DR5 was examined by fluorescence microscopy (scale bar: 200 μm). b Relative uptake efficiency of different polyplexes after
treatment with inhibitor (DR5) in cells. Cellular uptake without any inhibition was used as control (mean ± SD, n =3). c The cellular uptake of
Pluronic-PEI-DR5-TAT/DNA-cy3 complexes in HeLa, HepG2, and NIH 3T3 cells pretreated with DR5 was examined by fluorescence microscopy
(scale bar: 200 μm). d Relative uptake efficiency of different polyplexes after treatment with inhibitor (DR5) in cells. Cellular uptake without any
inhibition was used as control (mean ± SD, n = 3). Significance: **P < 0.01
Fig. 6 Flow cytometry study of cellular uptake of polyplexes. Total fluorescence intensity (n = 3, error bars represent standard deviation) after a
60-min incubation of DyLight-633-labeled PEI 2 kDa, Pluronic-PEI, and Pluronic-PEI-DR5-TAT at different concentrations (0, 0.20, 0.40, 0.80 μM) in
HeLa and HepG2 cells. Significance: **P < 0.01
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Fig. 8 Fluorescence microscopy images (scale bar: 200 μm) of HeLa cells after transfection with pEGFP-N2/PEI 25 kDa, pEGFP-N2/Pluronic-PEI or
pEGFP-N2/Pluronic-PEI-DR5, pEGFP-N2/Pluronic-PEI-TAT, and pEGFP-N2/Pluronic-PEI-DR5-TAT at different N/P ratios
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The cytotoxicity of HMW PEI is largely due to the high
density of amino groups. Pluronic-PEI is expected to
have lower cytotoxicity than HMW PEI with similar
molecular weight (25 kDa) [24]. The cytotoxicity of
Pluronic-PEI-DR5-TAT was measured in three cell lines
(HeLa, HepG2, and NIH 3T3) and compared to PEI
2 kDa, PEI 25 kDa, and Pluronic-PEI using the MTT
assay. The half maximal inhibitory concentration (IC50)
curves are shown in Fig. 5. The IC50 values of the carrier
materials (PEI 2 kDa, PEI 25 kDa, Pluronic-PEI, and
Pluronic-PEI-DR5-TAT) ranged from 16.32 to 294.7 μg/
mL (HeLa: 71.28, 17.24, 294.7, 286.9 μg/mL; HepG2:
69.22, 18.6, 217.1, 189.6 μg/ mL; NIH 3T3: 60.83, 16.32,Fig. 9 Fluorescence microscopy images (scale bar: 200 μm) of HepG2 cells
pEGFP-N2/Pluronic-PEI-DR5, pEGFP-N2/Pluronic-PEI-TAT, and pEGFP-N2/Plu606.6, 938.5 μg/mL). Among considerable prior attempts
have been made to modify PEI to reduce its cytotoxicity,
the most effective one is an introduction of phospholipid-
modified polyethylenimine [15, 20, 38, 39]; its IC50 value
is about 123 μg/mL. As shown in Fig. 5, PEI 25 kDa
showed clear dose-dependent cytotoxicity effects, and
most of the treated cells were killed at a concentration of
20 μg/mL. The cell viabilities after treatment with
Pluronic-PEI or Pluronic-PEI-DR5-TAT were more than
80 %, even up to a concentration of 60 μg/mL. This indi-
cated that they are suitable for gene delivery even at a high
concentration. The low cytotoxicity of Pluronic-PEI and
Pluronic-PEI-DR5-TAT may be the result of the lower
amino group density compared to HMW PEI. Moreover,after transfection with pEGFP-N2/PEI 25 kDa, pEGFP-N2/Pluronic-PEI or
ronic-PEI-DR5-TAT at different N/P ratios
Fig. 10 Fluorescence microscopy images (scale bar: 200 μm) of NIH 3T3 cells after transfection with pEGFP-N2/PEI 25 kDa, pEGFP-N2/Pluronic-PEI
or pEGFP-N2/ Pluronic-PEI-DR5, pEGFP-N2/Pluronic-PEI-TAT, and pEGFP-N2/Pluronic-PEI-DR5-TAT at different N/P ratios
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(HeLa and HepG2) were significantly higher than in nor-
mal cells (NIH 3T3); in other words, cells which expressed
high levels of DR5 were more sensitive to Pluronic-PEI-
DR5-TAT than the DR5-negative NIH 3T3 cells. This
suggests that the binding ability and specificity of
Pluronic-PEI-DR5-TAT to DR5 reduces toxicity in normal
cells. These results indicated that Pluronic-PEI-DR5-TAT
is an ideal vector for gene transfection because its low tox-
icity to normal cells will allow a higher dose of Pluronic-
PEI-DR5-TAT to be used.
Cellular Uptake and Competition Assay
Efficient entry of complexes into cells is a critical step for
gene transcription. Many factors, such as particle size, zeta
potential, and ligand-receptor interaction, have a huge ef-
fect on cell uptake [36]. HeLa and HepG2 cells were usedFig. 11 Luciferase activity analysis (mean ± SD, n = 4) after transfection of H
pGL-3/Pluronic-PEI-TAT, or pGL-3/Pluronic-PEI-DR5-TAT at different N/P ratioas model tumor cells to investigate the in vitro cellular up-
take of Pluronic-PEI-DR5-TAT. As shown in Fig. 6, at the
same concentrations, PEI 25 kDa and Pluronic-PEI had
similar cell uptake efficiency in HeLa and HepG2 cells,
but Pluronic-PEI-DR5-TAT had significantly higher cell
uptake efficiency than both. Our results suggest that DR5-
TAT modification of Pluronic-PEI enhances transfer
across the cell membrane and increases the internal-
ization of Pluronic-PEI-DR5-TAT owing to specific
ligand-receptor binding, DR5-mediated endocytosis medi-
ated, and the enhanced cell penetration due to TAT.
To confirm the specificity of the interaction between
Pluronic-PEI-DR5-TAT/DNA complexes and the targeted
cells, a competition assay was performed using free DR5.
The uptake efficiency of Pluronic-PEI-DR5-TAT/DNA-cy3
and Pluronic-PEI/DNA-cy3 complexes (N/P ratio of 15)
was investigated using DR5 as a competitor. The resultseLa with pGL-3/PEI 25 kDa, pGL-3/Pluronic-PEI, pGL-3/Pluronic-PEI-DR5,
s. *P < 0.05, **P < 0.01
Fig. 12 Luciferase activity analysis (mean ± SD, n = 4) after transfection of HepG2, with pGL-3/PEI 25 kDa, pGL-3/Pluronic-PEI, pGL-3/Pluronic-PEI-
DR5, pGL-3/Pluronic-PEI-TAT, or pGL-3/Pluronic-PEI-DR5-TAT at different N/P ratios. *P < 0.05, **P < 0.01
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the fluorescence intensity were quantitative determined
(Fig. 7c, d). The cell uptake efficiency of Pluronic-PEI-
DR5-TAT/DNA complexes in HepG2 and HeLa cells
pretreated with DR5-TAT was significantly inhibited com-
pared with untreated cells (Fig. 7b, d), whereas that of
Pluronic-PEI/DNA complexes was only slightly changed
or unchanged (Fig. 7a, c). It is worth mentioning that the
cellular uptake efficiency of neither Pluronic-PEI-DR5-
TAT/DNA complexes nor Pluronic-PEI/DNA complexes
in NIH 3T3 cells (DR5-negative) was affected by DR5.
Therefore, the availability of DR5 was essential for the
entry of Pluronic-PEI-DR5-TAT/DNA complexes into
tumor cells through a receptor-mediated delivery system.
Transfection Efficiency
The transfection efficiency of polymer/pEGFP-N2 (at vari-
ous N/P ratios) in HeLa, HepG2, and NIH 3T3 cells was
observed by fluorescence microscopy. Figures 8, 9, and 10
show that gene transfection efficiencies of all five polymersFig. 13 Luciferase activity analysis (mean ± SD, n = 4) after transfection of N
PEI-DR5, pGL-3/Pluronic-PEI-TAT, or pGL-3/Pluronic-PEI-DR5-TAT at different(PEI 25 kDa, Pluronic-PEI, Pluronic-PEI-DR5, Pluronic-
PEI-TAT, and Pluronic-PEI-DR5-TAT) all increased in line
with N/P ratio in all five cell lines. The pEGFP reporter
gene expression in HeLa and HepG2 cells treated with
Pluronic-PEI-DR5-TAT complexes was higher than PEI
25 kDa, Pluronic-PEI complexes, Pluronic-PEI-DR5, or
Pluronic-PEI-TAT at all N/P ratios (Figs. 8 and 9). No ob-
vious differences were observed between the same five
polymer/DNA complexes in NIH 3T3 cells (Fig. 10).
To evaluate the transfection efficiency mediated by
Pluronic-PEI-DR5-TAT, a luciferase assay was also per-
formed in HeLa, HepG2, and NIH 3T3 cells, and the re-
sults are shown in Fig. 11. The complexes possessed the
highest transfection efficiency at an N/P ratio of 15. The
transfection efficiency of Pluronic-PEI-DR5-TAT was
shown to be significantly higher than that of Pluronic-
PEI-DR5 or Pluronic-PEI-TAT (*P < 0.05) and much
significantly higher than that of PEI 25 kDa or Pluronic-
PEI in HeLa and HepG2 cells (**P < 0.01), while PEI
25 kDa and Pluronic-PEI demonstrated similar transfectionIH 3T3 cells with pGL-3/PEI 25 kDa, pGL-3/Pluronic-PEI, pGL-3/Pluronic-
N/P ratios
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15, the luciferase expression induced by transfection with
Pluronic-PEI-DR5-TAT/pGL3-control complexes was 1.92
and 1.30 times more than that induced by Pluronic-PEI-
DR5 or Pluronic-PEI-TAT, 5.5 and 5.9 times more than
that induced by Pluronic-PEI or PEI 25 kDa, respectively.
In HepG2 cells, Pluronic-PEI-DR5-TAT/pGL3-control
complexes induced 2.50 and 1.21 times more than that in-
duced by Pluronic-PEI-DR5 or Pluronic-PEI-TAT, 10.1 and
11.2 times more luciferase expression than Pluronic-PEI or
PEI 25 kDa, respectively. There was no significant differ-
ence in the luciferase expression induced by the three
vectors in NIH 3T3 cells (Fig. 13). Since there is over-
expression of DR5 on HeLa and HepG2 cells, the multi-
functional DR5-TAT may also promote cargo transport via
receptor-mediated endocytosis [16]. Moreover, the TAT
peptide could increase membrane penetration, and it is the
combined effect of DR5 and TAT that improves the gene
transport ability of DR5-TAT-modified Pluronic-PEI. These
results indicate that Pluronic-PEI conjugated with DR5-
TAT peptide has excellent gene transfection efficiency and
a high level of targeting specificity to DR5-positive cells.
Conclusions
A novel non-viral gene vector, Pluronic-PEI-DR5-TAT,
was successfully constructed by cross-linking LMW-PEI
with Pluronic and further coupled a multifunctional
peptide DR5-TAT to form the copolymer for targeting
DR5-positive cancer cells and increasing cellular uptake
efficiency, which is believed to increase gene transfection
efficiency and reduce toxicity to normal cells. We have
confirmed that Pluronic-PEI-DR5-TAT could easily form
complexes with DNA and that it had appropriate bio-
physical characteristics for effective gene delivery. More-
over, the novel gene delivery system showed much lower
cytotoxicity on DR5-negative NIH 3T3 cells, significantly
higher cellular uptake efficiency and gene transfection
efficiency than PEI 25 kDa and Pluronic-PEI on HeLa
and HepG2 cells than over-expression of DR5. In sum-
mary, Pluronic-PEI-DR5-TAT is a potential DR5 select-
ive targeting gene vector for cancer gene therapy.
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